Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
5,407 EUR | -0,73% | -0,24% | -.--% |
07/05 | Koersdoel AstraZeneca verhoogd; Antofagasta verlaagd | AN |
03/05 | AIB GROUP : Sterkere inkomstengroei en gunstige risicokosten |
Omzet 2024 * | 4,54 mld. 4,89 mld. | Omzet 2025 * | 4,33 mld. 4,66 mld. | Marktkapitalisatie | 12,07 mld. 13 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 1,74 mld. 1,87 mld. | Nettowinst (verlies) 2025 * | 1,54 mld. 1,66 mld. | EV/omzet 2024 * | 2,66 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 2,79 x |
K/w-verhouding 2024 * |
7,01
x | K/w-verhouding 2025 * |
7,29
x | Werknemers | - |
Dividendrendement 2024 * |
5,99% | Dividendrendement 2025 * |
6,35% | Vrij verhandelbaar | 67,47% |
Recentste transcriptie over AIB Group plc
1 dag | -0,73% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Colin Hunt
CEO | Chief Executive Officer | 54 | 01-01-16 |
Donal Galvin
DFI | Director of Finance/CFO | 50 | 01-09-13 |
Graham Fagan
CTO | Chief Tech/Sci/R&D Officer | - | 19-10-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Fergal O’Dwyer
BRD | Director/Board Member | 64 | 22-01-21 |
James Pettigrew
CHM | Chairman | 65 | 28-10-21 |
Brendan McDonagh
BRD | Director/Board Member | 66 | 27-10-16 |
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+16,85% | 571 mld. | |
+14,20% | 301 mld. | |
+18,59% | 252 mld. | |
+25,74% | 216 mld. | |
+21,29% | 183 mld. | |
+25,50% | 170 mld. | |
+9,52% | 162 mld. | |
+5,28% | 146 mld. | |
-15,88% | 131 mld. |